Introduction
Testicular germ cell tumor (TGCT)-derived embryonal carcinoma (EC) is the most common malignant neoplasm in males between the ages of 15 and 35 years (Huyghe et al., 2003) . This solid tumor is highly aggressive but curable with cisplatin-based chemotherapy (Einhorn, 2002) . The molecular basis for germ cell tumorigenesis and hypersensitivity to therapy is poorly understood (Chaganti and Houldsworth, 2000; Jones and Vasey, 2003) . EC characteristically harbors abundant levels of wild-type p53, suggesting a lack of mutational selective pressure during tumor progression (Heimdal et al, 1993; Peng et al., 1993) . This has led to the proposal that EC has suppressed basal p53 activity (Lutzker and Levine, 1996; Curtin et al., 2001) . Despite this apparent latency, p53 in TGCTs retains the ability to be activated in response to various cellular stresses which may account for the high sensitivity of TGCTs to cisplatin-based therapy (Chresta et al., 1996; Lutzker and Levine, 1996; Houldsworth et al., 1998; Zamble et al., 1998; Zeng et al., 2000; Curtin et al., 2001; Lutzker et al., 2001) . The mechanism by which EC maintains p53 in a repressed state, and how this is relieved during therapy remains unclear. Several EC cell lines are pluripotent and retain the potential to terminally differentiate in response to all-trans retinoic acid (RA) and other defined treatments (Andrews, 2002) . It has been suggested that the curability of TGCTs is linked to their germ cell origin and retained developmental potential (Jones and Vasey, 2003) . In our prior study, we provided evidence that RA and cisplatin converge on a common pathway involving p53 in human EC cells. RA was found to activate the transactivation function of p53 in the human EC cell line, NT2/D1, in a retinoid receptor-dependent manner (Curtin et al., 2001) . A derived RA-resistant line, NT2/ D1-R1 was deficient in this activity and was found to be coresistant to cisplatin (Curtin et al., 2001) .
Derivatives of vitamin A, the retinoids, have been shown to have activity as both chemotherapeutic and chemopreventive agents (Hong and Sporn, 1997; Sun and Lotan, 2002) . Retinoids function as ligands for the retinoic acid receptors (RARs), a family of nuclear receptors involved in regulating cell cycle proliferation, growth suppression, and differentiation (Mangelsdorf et al., 1994) . While many solid tumors are initially responsive to retinoids, acquired retinoid resistance is common (Lippman et al., 2001; Freemantle et al., 2003) . In some cases, resistance has been associated with loss of p53 function. For example, although retinoids are effective in the treatment of premalignant lesions of the head and neck and oral leukoplakia, aberrant p53 expression in these pathologies often predicts retinoid resistance (Shin et al., 1997 (Shin et al., , 2000 Nason-Burchenal and Dmitrovsky, 1999) . These clinical findings suggest a possible role for p53 in retinoid responses in certain tumor types.
RA treatment of NT2/D1 cells signals arrest in the G1 phase of the cell cycle, terminal differentiation along a neuronal pathway, and loss of tumorigenicity (Andrews, 1984; Spinella et al., 1999) . In our prior study we showed that the transactivation activity of p53 was enhanced by RA in a dose-dependent manner (Curtin et al., 2001) . RA also enhanced the expression of several p53 target genes in NT2/D1, but not RAresistant NT2/D1-R1 cells that were devoid of RAmediated activation of p53 (Curtin et al., 2001 , Freemantle et al., 2002 . Inhibiting p53 function suppressed optimal RA-mediated differentiation, suggesting that p53 participates in RA-mediated differentiation of EC (Curtin et al., 2001) . RA-resistant NT2/D1-R1 cells do not undergo growth arrest, differentiation, or loss of tumorigenicity in response to RA due to a defect in RARg expression (Moasser et al., 1996) . However, restoration of RARg expression restores RA-sensitivity to these cells (Moasser et al., 1995; Spinella et al., 1998) Restoration of RAR expression led to restoration of p53 activation, suggesting that activation of p53 by RA is RAR-dependent (Curtin et al., 2001) . Furthermore, RAresistant NT2/D1-R1 cells displayed a striking crossresistance to cisplatin treatment (B7-10-fold) relative to parental NT2/D1 cells (Curtin et al., 2001) . Dominantnegative p53 reduced cisplatin-mediated cytotoxicity in NT2/D1 cells. Together this data suggested that p53 is important for RA and cisplatin responses in NT2/D1 cells, and that crossresistance to RA and cisplatin may be due to a common defect in p53 regulation in NT2/D1 cells. However, in contrast to the situation with cisplatin, classic mechanisms of p53 activation were not involved in RA-mediated activation of p53 in NT2/ D1 cells (Curtin et al., 2001) .
The current study addresses the mechanism of p53 repression in human EC. The p53 protein consists of several well-defined domains that include a N-terminal transactivation domain, a proline-rich domain, a central sequence-specific DNA-binding domain, an oligomerization domain and a C-terminal regulatory domain (Oren, 2003) . To identify a potential region of p53 that mediates latency, activities of various p53 deletion mutants were assessed. Removal of a small peptide region in the N-terminal region of p53 relieved the basal repression of p53 characteristic of NT2/D1 cells. A notable finding was that this peptide region of p53 mediated repression when fused to the potent transactivator VP16, indicating that this peptide can act as a heterologous repressor. We have named this domain the p53 N-terminal Repression Domain or p53-NRD.
The p53-NRD exhibited varying degrees of repressor activity in different cell contexts, with the most prominent repressor activity in human EC cells. Although RA alone did not reverse repression, the repressor activity of this peptide was relieved in the presence of RA and the histone deacetylase inhibitor trichostatin A (TSA). Interestingly, RA plus TSA treatment did not relieve p53-NRD-mediated repression in NT2/D1-R1 cells, but did relieve repression when RARg was reintroduced into the cells. Taken together, these results suggest that a previously undercharacterized domain of p53 may participate in the basal repression of p53 in EC cells.
Results
The p53 DNA-binding domain is dispensable for RA-induced p53 activation
We have previously demonstrated that RA activates p53 transactivation activity in a dose-dependent manner in the human EC cell line NT2/D1 and that RA does not affect p53 expression levels (Curtin et al., 2001) . RA mediates robust activation of gal4-p53 transactivation activity in a gal4-based assay, suggesting that RAmediated enhancement of p53 activity occurs downstream of p53-DNA binding (Curtin et al., 2001) . A recent report suggested that RA can regulate the nuclear localization of p53 in the neuroblastoma cell line SH-SY5Y (Ronca et al., 1999) . To determine if RA treatment affected p53 localization in human EC, NT2/D1 cells were treated with RA for 48 h, and nuclear and cytoplasmic protein fractions were analysed for p53 expression by Western analysis. A greater proportion of p53 resides in the nucleus of NT2/D1 cells, and RA had no effect on p53 nuclear localization or overall p53 levels ( Figure 1a) . Thus, the mechanism responsible for RA-induced activation of p53 in EC does not involve increased p53 translocation to the nucleus or increased p53 stability.
To begin to address whether p53 repression and its reversal by RA could be ascribed to a specific domain of p53, four gal4-p53 deletion constructs were generated and tested (Figure 1b and 1c) . Full-length p53 transactivation activity was induced approximately 10-fold with RA as shown previously (Figure 1c and Curtin et al., 2001) . In contrast, deletion of the transactivation and proline-rich regions of p53 (D1-89) or deletions of the nuclear localization, oligomerization, and C-terminal basic regions (D294-393) of p53 resulted in complete loss of basal and RA-induced p53 activity. Interestingly, when the transactivation and proline-rich domains of p53 where alone fused to gal4, an approximately 100-fold increase in p53 basal activity was observed in NT2/D1 cells (Figure 1c ). RA treatment did not increase this activity further suggesting maximal transactivation of this construct. Deletions of the entire core DNA-binding domain of p53 (D117-274) did not effect either basally repressed or RA induced p53 transactivation function in NT2/D1 cells (Figure 1c ). This confirms that RA induced p53 transactivation activity independently of increased p53-DNA interactions (Curtin et al., 2001) . Additionally, effects of RA on p53 DNA binding were not observed in gel shift analyses (data not shown). Together, these data strongly suggest that RA-mediated activation of p53 is not dependent on increased p53-DNA interactions.
A specific region of p53 confers repression upon p53 in EC Since deletion of amino-acid residues 117-274 of p53 did not alter basal or RA-induced p53 activity (Figure 1c) , this core DNA-binding domain deletion was used as the basis for the construction of a series of gal4-p53 deletion mutants. Progressively larger truncations were made toward the C-or N-terminus of gal4-p53D117-274, and Figure 1 RA activates the transactivation activity of p53 independent of the p53 DNA-binding domain and effects on p53 nuclear localization. (a) RA does not affect p53 nuclear localization in NT2/D1 cells. NT2/D1 cells were treated with 10 mM RA or control (DMSO) for the indicated times (h). Nuclear and cytosolic fractions were prepared and p53 expression levels were assessed by Western analysis. (b) Schematic of p53 deletion mutants used in this study. Well-characterized domains of p53 are indicated and include the transactivation (TA), proline rich (PXXP), nuclear localization (NL), and oligomerization (Oligo) domains. Data for basal and RAinduced p53 transactivational activity for each construct is indicated. (c) The p53 sequence-specific DNA-binding domain is dispensable for RA activation of p53. NT2/D1 cells were cotransfected with a gal4-Luc reporter and either gal4-p53 (full length) or gal4-p53 deletion mutants in the absence or presence of increasing doses of RA (0, 1.0, 10 mM RA). Deletion of residues 1-89 and 294-393 completed abolished basal and RA-induced activity. Deletion of residues 102-393 resulted in a substantial increase in basal p53 activity. Deletion of the core DNA-binding domain of p53 did not effect basal and RA-induced activity. For all transfections, each point is the average of three independent determinations. Results were corrected for b-galactosidase activity. Error bars are standard error of the mean (s.e.m.) the basal ( Figure 2a ) and RA-induced ( Figure 2b ) activities were assessed. The deletion series is diagrammatically represented in Figure 1b . Deletion of residues toward the C-terminus of p53 as far as residue 354 did not affect either the basal or RA-inducible activity of gal4-p53 (Figure 2a and 2b) . However, when a small region in the N-terminus was deleted (residues 106-117), relief of the basal repression of p53 activity characteristic of EC was observed ( Figure 2a ). This deletion was only partially responsive to RA mediated activation compared to full-length p53 (Figure 2b ). These results of the deletion studies are summarized in Figure 1B . The data are consistent with RA activation of p53 being dependent on the known complex interactions between the transactivation domain and the extreme C-terminal basic domain of p53, since transactivation was only disrupted in constructs where these domains were deleted. We focused on a region within the N-terminus of p53 since in the two constructs where this region was deleted, D102-393 and D106-275, the basal activity of p53 was increased approximately 100-fold and 20-fold, respectively. Western analysis confirmed that the deletion constructs were expressed to comparable levels in NT2/D1 cells, and that the protein products were of the expected size ( Figure 2c ).
The repressive domain of p53 acts as a heterologous repressor of transcription factor activity
These data suggest that residues 105-116 of p53 confer basal repression upon p53 in NT2/D1 cells. This region of p53 lies between the proline-rich domain and the core DNA-binding domain (Benard et al., 2003) . This entire The ability of RA to induce activity of various p53-deletion constructs. NT2/D1 cells were cotransfected with a gal4-Luc reporter and expression plasmids for various gal4-p53 truncation peptides in the presence or absence of 10 mM RA. Data are represented as fold change upon RA treatment as compared to vehicle control. Each point is the average of at least three independent determinations. All results were corrected for b-galactosidase activity. Error bars are standard deviation. (c) Expression of gal4-p53 deletion proteins in NT2/D1 cells are similar and of the expected size. NT2/D1 cells were transfected with the indicated expression plasmids, harvested 24 h later, and fusion protein expression was determined via Western blotting using an anti-gal4 antibody Figure 3 p53-NRD acts as a heterologous repressor (a) p53-NRD substantially represses the transactivation activity of the VP16-Activation Domain (VPAD). p53-NRD confers an approximate 15-fold level of repression when fused to the C-terminus of the gal4-VPAD (gal4-VPAD-NRD). A similarly sized C-terminal extension to VPAD (gal4-VP-MYC) did not affect VPAD activity. Each point is the average of at least three independent determinations. Results were corrected for b-galactosidase activity. Error bars are standard deviation. (b) Activity of gal4-VPAD and gal4-VPAD-NRD is not effected by RA treatment. Each point is the average of at least three independent determinations. All results were corrected for b-galactosidase activity. Error bars are standard deviation region (residues 90-116) was fused to the C-terminus of the VP16 Activation Domain (gal4-VPAD-NRD) to determine whether the region acted as a heterologous repressor of transcription factor activity. Fusion of p53 residues 90-116 to the gal4-VPAD resulted in a 10-20-fold repression of gal4-VPAD activity (Figure 3a) . This repression was likely not due to steric hindrance since a gal4-VPAD protein fused with a 27 residue myc-his tag (gal4-VPAD-MYC) was as active as gal4-VPAD (Figure 3a) . Owing to the heterologous repressive activity of this p53 domain, and its location within the N-terminal half of the p53 protein, we have designated the peptide fragment from residues 90-116 as the p53 Nterminal repression domain (p53-NRD). In contrast to the ability of RA to activate full-length p53, RA was unable to reverse p53-NRD-mediated repression (Figure 3b ).
EC cells display prominent p53-NRD-mediated repression
The p53-NRD may play an important role in ECmediated repression of p53. To investigate how specific this repression was to EC, the potential of the p53-NRD to repress VPAD activity in a variety of cell lines was assayed (Figure 4 ). p53-NRD-mediated repression of VPAD activity was greatest in NT2/D1 cells, with a typical 10-20-fold level of repression observed. In the NT2/D1 RA-resistant derivative NT2/D1-R1 cell line, which harbors wild-type p53 (Curtin et al., 2001 ), p53-NRD-mediated repression was approximately twelvefold. In the human breast cancer cell line MCF-7, which harbors wild-type p53, and the immortalized human lung epithelial cell line BEAS2-B, which has wild-type p53, p53-NRD-mediated repression was approximately five-fold. In CHO cells, p53-NRD-mediated repression was approximately three-fold relative to VPAD activity. Interestingly, we have previously shown that in CHO cells full-length gal4-p53 activity is constitutively high compared to NT2/D1 cells and was not enhanced with RA treatment (Curtin et al., 2001) .
Identification of minimal p53-NRD elements
The p53-NRD is a 27-residue peptide with no obvious functional motifs. To investigate whether any specific residues were required for p53-NRD-mediated repression, alanine substitutions were performed, in triplicate, along the length of the p53-NRD in the context of gal4-VPAD-NRD. In total, nine VPAD-NRD mutants were created (see inset of Figure 5a ). All mutants of gal4-VPAD-NRD behaved as the parental peptide (Figure 5a ), suggesting that no single residue alone was critical for p53-NRD-mediated repression. It is possible, however, that several nontandem residues act coordinately to mediate p53-NRD repression.
The possibility that a smaller segment of the p53-NRD mediated this repressive activity was investigated. The indicated p53-NRD truncations were engineered and assayed for ability to confer repression to the VPAD. As depicted in Figure 5b , truncations within the p53-NRD were shown to relieve p53-NRD-mediated repression. The p53-NRD is comprised of p53 residues 90-116. When residues 107-116 were removed (NRDCut1), p53-NRD-mediated repression was relieved by approximately 50%. A larger truncation that removed residues 100-116 (NRDCut2) fully relieved p53-NRD-mediated repression as there was no significant difference between gal4-VPAD-MYC and NRDCut2 (Figure 5b ). These results suggest that a minimal p53-NRD element exists, and is comprised of p53 residues 100-116. It is possible that all residues within this peptide domain are required for maximal p53-NRD-mediated repression, or various subsets of the residues within the domain are necessary for p53-NRDmediated repression.
RA and TSA cooperatively relieve p53-NRD-mediated repression
Based on our prior results that indicated that RA could activate basally repressed full-length p53 in NT2/D1 cells, we asked whether RA could relieve p53-NRDmediated repression. Treatment of NT2/D1 cells with 10 mM RA had no effect on gal4-VPAD-NRD activity (Figure 6a ). Transcriptional repressors often exhibit histone deacetylase (HDAC) activity. To explore the possibility that HDACs contribute to p53-NRDmediated repression, the activity of gal4-VPAD-NRD in the presence of the HDAC inhibitor TSA was measured in NT2/D1 cells (Figure 6a ). While gal4-VPAD activity was not affected by TSA treatment (data not shown), gal4-VPAD-NRD activity was increased with TSA in a dose-dependent manner (Figure 6a ). At 100 and 200 nM TSA dosages, gal4-VPAD-NRD activity was restored to nearly 50% relative to gal4-VPAD (Figure 6a ). Previous studies have demonstrated that RA and TSA can act in a cooperative manner to induce differentiation of various tumor cells including human acute promyelocytic leukemia (APL) (Lin et al., 1998) . To determine if RA treatment would synergize with TSA in relieving p53-NRD-mediated repression, NT2/ D1 cells transfected with gal4-VPAD-NRD were treated with increasing doses of TSA, in the presence of 10 mM RA. In the presence of 10 mM RA and 100 nM TSA, p53-NRD-mediated repression of VP-AD activity was fully relieved (Figure 6a ). These data suggest that HDACs may be involved in mediating the repressive activity of the p53-NRD.
RA enhanced p53 transactivation activity and induced p53 target gene expression in NT2/D1, but not NT2/D1-R1 cells, despite the fact that NT2D1-R1 cells express high levels of wild-type p53 (Curtin et al., 2001 ). NT2/D1-R1 cells are deficient in the expression of RARg, and engineered expression of RARg can restore the ability of RA to signal growth suppression and differentiation in these cells (Moasser et al., 1995 (Moasser et al., , 1996 Spinella et al., 1998) and RARg restored RAmediated activation of full-length p53 (Curtin et al., Figure 5 p53-NRD residues 100-116 are important for p53-NRDmediated repression in human EC. (a) Alanine substitutions along the p53-NRD have minimal effects on p53-NRD-mediated repression. Alanine substitutions were performed in triplicate along the length of the p53-NRD. NT2/D1 cells were transfected with a gal4-luciferase reporter plasmid and different gal4-VPAD-NRD mutants, and assessed for basal luciferase activity. All results were corrected for b-galactosidase activity. Error bars are standard deviation. Inset, amino-acid sequence of p53-NRD and alanine substitution and deletion mutants. (b) Deletion of a segment of the p53-NRD abrogates its ability to repress transcription. Expression plasmids for gal4-VPAD-NRD truncation proteins were assayed for repressive activity in NT2/D1 cells, as compared to gal4-VPAD-NRD repression activity. Deletion of p53 residues 100-116 (NRD-CUT2) within the p53-NRD restored activity to gal4-VPAD. Each point is the average of three independent determinations. Results were corrected for b-galactosidase activity. Error bars are standard deviation Figure 6 RA and TSA cooperate to relieve p53-NRD-mediated repression in RA-sensitive but not RA-resistant human EC cells (a) RA and TSA cooperate to relieve p53-NRD-mediated repression. NT2/D1 cells were cotransfected with a gal4-Luc reporter and either gal4-VPAD or gal4-VPAD-NRD expression vectors in the absence or presence of RA (10 mM), and increasing doses of TSA (25, 50, 100 and 200 nM), alone and in combination. RA treatment did not affect VPAD-NRD activity. TSA alone was able to partially relieve p53-NRD-mediated repression and combined RA and TSA treatment fully relieved p53-NRD-mediated repression. VPAD activity was not affected by these treatments (data not shown). Each point is the average of three independent determinations. Results were corrected for b-galactosidase activity. Error bars are s.e.m. (b) TSA and RA combined treatment fails to relieve p53-NRD-mediated repression in NT2/D1-R1 cells. NT2/D1-R1 cells were cotransfected with a gal4-Luc reporter and either gal4-VPAD or gal4-VPAD-NRD expression vectors in the absence or presence of RA (10 mM), and increasing doses of TSA (25, 50, and 100 nM), alone or in combination. RA treatment did not affect gal4-VPAD-NRD activity in NT2/D1-R1 cells. Increasing doses of TSA had no effect on p53-NRD-mediated repression, and combination treatment had no effect on gal4-VPAD-NRD activity. Results were corrected for b-galactosidase activity. Error bars are standard deviation 2001). Interestingly, p53 was also less responsive to cisplatin in NT2/D1-R1 cells as compared to NT2/D1 cells and NT2/D1-R1 cells were 10-fold resistant to cisplatin-mediated cytotoxicity (Curtin et al., 2001) . Since these data imply that NT2/D1-R1 cells may harbor a defect in RA-and cisplatin-mediated p53 activation, the ability of RA and TSA to reverse p53-NRD-mediated repression was investigated in this line. In NT2/D1-R1 cells, neither RA nor TSA alone or in combination had the ability to relieve p53-NRDmediated repression (Figure 6b ), although the extent of NRD-mediated repression was less pronounced in NT2/D1-R1 cells compared to NT2/D1 cells. Whether RARg plays a role in sensitizing the p53-NRD to RA and TSA in NT2/D1-R1 cells was investigated. Overexpression of RARg relieved p53-NRD-mediated repression in NT2/D1-R1 cells in the presence of RA and TSA (Figure 7) . TSA had no effect on activity of PSG5 alone (data not shown). These findings further support a role for RARs in relieving repression of p53 in EC cells.
Discussion
Human EC are exquisitely sensitive to cisplatin-based therapy (Einhorn, 2002) . It has been proposed that EC sensitivity to cisplatin may be due to the presence of abundant, wild-type p53 (Chresta et al., 1996; Lutzker and Levine, 1996; Houldsworth et al., 1998; Zamble et al., 1998; Zeng et al., 2000; Curtin et al., 2001; Lutzker et al., 2001) , although conflicting reports on the relative importance of p53 in cisplatin response do exist (Burger et al., 1998 (Burger et al., , 1999 Kersemaekers et al., 2002) . Curability of human EC has been proposed to be linked to their retained maturation potential (Jones and Vasey, 2003; Spinella et al., 2003) . Cultured human EC differentiate in response to RA treatment, undergoing arrest in the G1 phase of the cell cycle, differentiation along a neuronal pathway, and loss of tumorigenicity (Spinella et al., 1999 .
We previously demonstrated that RA activates the innate transactivation function of p53, and that this pathway is important for optimal RA responses in NT2/ D1 cells (Curtin et al., 2001) . In this study, a functional mapping approach was used to determine whether a specific region, or regions, of p53 mediate latency or RA activation of p53 in EC cells. This screen identified a small peptide fragment of p53, here named p53-NRD. The p53-NRD is located between the proline-rich domain and the core DNA-binding domain of p53 and when deleted led to an increase in basal p53 activity. This region is part of a fully folded independent domain of unknown function (Bargonetti et al., 1993; Pavletich et al., 1993; Cho et al., 1994) . Importantly, p53-NRD conferred repression of transcriptional activity when transferred to the potent transactivation domain of VP16. While this repression is observed in a variety of cell contexts, it is most notable in NT2/D1 cells. The histone deacetylase inhibitor TSA relieved the repression conferred by the p53-NRD, suggesting a possible role for deacetylase-associate corepressors and chromatin remodeling.
It has been suggested that EC possess wild-type, latent p53 (Lutzker and Levine, 1996; Curtin et al., 2001) . The current finding that a small region of p53 confers repression supports the view that a specific region of p53 may contribute to p53 repression in EC, and perhaps in other tumor types that harbor wild-type p53. It is interesting to note that of the various tumor cells tested, the newly identified p53-NRD represses transactivation most potently in NT2/D1 cells. This suggests that the apparent latency conferred upon p53 by EC relative to other tumor types may occur in part at this region of p53. It would be of interest to expand the functional assessment of p53-NRD in cell lines that have inactivated p53 by various mechanisms. It is important to clarify that although there is no requirement for the p53 DNA-binding domain per se for activation of p53 by RA or p53-NRD-mediated repression, both activities are dependent on recruitment to DNA (for example via gal4-DBD). Thus p53-NRD repression is predicted to be mediated at the level of p53 target gene promoters. It will be of interest to determine whether a unique protein-protein interaction occurs at this region of p53. Targeted disruption of such an interaction may have therapeutic applications.
The p53-NRD residues 90-116 are well conserved among mammalian species of p53. Interestingly, while p63 and p73 share a high degree of conservation with p53 across functional domains, they lack the NRD region (Benard et al., 2003) . This suggests that the NRD Figure 7 RARg expression sensitizes p53-NRD to TSA and RA in NT2/D1-R1 cells. NT2/D1-R1 cells were cotransfected with a gal4-Luc reporter, a gal4-VPAD-NRD expression vector, and either PSG5-RARg or empty PSG5 expression vectors. Cells were treated with either RA (10 mM), increasing doses of TSA (0.001 and 10 nM), or combinations of RA (10 mM) and TSA (0.001, 0.1, and 10 nM). RA treatment did not affect gal4-VPAD-NRD activity in the absence of RARg, but slightly relieved repression in the presence of RARg. Increasing doses of TSA in combination with RA in the presence of RARg led to a substantial relief of p53-NRD-mediated repression. Results were corrected for b-galactosidase activity. Error bars are standard deviation region may be responsible for functions that are unique to p53 among members of the p53 family. The region is rarely mutated in human cancers (Varley, 2003) , and the amino-acid residues that comprise this domain do not contain any obvious functional motifs. Protein-protein interactions or post-translational modifications have not been reported to occur within this region of p53, although a region within the p53-NRD sequence has been shown to mediate degradation of p53 in response to oncogenic stress . In an effort to define more precisely the residues within the p53-NRD responsible for repressor activity, gross mutations within the p53-NRD identified residues 100-116 as important for p53-NRD-mediated repression. It will be of interest to extend these findings to determine whether p53 deleted of NRD still interacts with and represses a known repression target such a survivin (Hoffman et al., 2002) or a repression consensus sequence (Johnson et al., 2001) .
HDACs function to deacetylate lysine residues of histone molecules, which is thought to lead to chromatin condensation and subsequent inhibition of transcription (Glass and Rosenfeld, 2000) . HDAC inhibitors such as TSA can facilitate the transcription of genes which would otherwise be repressed (Glass and Rosenfeld, 2000) . TSA has been used both in the laboratory and clinic as a therapeutic agent useful in promoting gene expression (Kouraklis and Theocharis, 2002) . In a dosedependent manner, TSA has the ability to alleviate p53-NRD-mediated repression by nearly 50% as a single agent. While the presence of RA alone has little effect on p53-NRD activity, RA and TSA together fully relieve p53-NRD-mediated repression in NT2/D1 cells. These findings suggest that HDACs or other proteins involved in suppression of transcription may play a critical role in NRD-mediated repression. An influence for HDACs in regulating p53 function is beginning to emerge (Ho and Benchimol, 2003) . Recent reports indicated that HDACs repress basal p53 activity by deacetylating residues within the C-terminus of p53. This occurs either by direct recruitment of HDACs or by recruitment of the adapter proteins mSin3a and PID (Juan et al., 2000; Luo et al., 2000; Zilfou et al., 2001) . Thus, HDAC recruitment may have dual mechanisms of p53 repression, targeting the p53 molecule itself and/or histones in the vicinity of p53 target gene promoters (Brooks and Gu, 2003) . Although the domains of p53 required for HDAC-complex recruitment are in most cases not clearly defined, mSin3a has been shown to bind the proline-rich domain of p53 which resided outside of the p53-NRD region. In addition, Sir2a, a TSA-resistant, NAD-dependent histone deacetylase, can both deacetylate p53 and attenuate its transcriptional activity (Luo et al., 2001; Vaziri et al., 2001) .
RA in combination with HDAC inhibitors has shown promise for basic and clinical applications. Ferrara et al. (2001) demonstrated that RA-resistant primary blasts derived from AML patients underwent RA-dependent maturation in the presence of HDAC inhibitors. While RA induces differentiation in APL cells as a single agent, TSA and RA synergize to induce differentiation in APL cells (Lin et al., 1998) . Furthermore, clinical studies have demonstrated that RA refractory APL cases undergo remission in response to RA and HDAC inhibitor combination therapy (Petti et al., 2002; Zhou et al., 2002) . These findings illustrate the potential for combining 'differentiation therapies' with 'transcription therapies' in the treatment of malignancies refractory to single-agent retinoid treatment. Current clinical trials are examining the use of HDAC inhibitors as single agents, as well as in combination therapies (Pandolfi, 2001; Johnstone, 2002) . Thus, the ability of RA and TSA to alleviate p53-NRD-mediated repression warrants further investigation into the mechanism of this cooperative relationship.
In NT2/D1-R1 cells, RA and TSA were unable to relieve p53-NRD-mediated repression. Interestingly, overexpression of RARg in NT2/D1-R1 cells sensitized the p53-NRD to RA and TSA. This finding is notable because it suggests that RA-mediated reversal of p53-NRD repression is RAR dependent. Furthermore, the relief of p53-NRD-mediated repression in the presence of RA and RARg is consistent with the ability of restored RARg expression to restore RA activation of p53 in NT2/D1-R1 cells (Curtin et al., 2001) , and the established ability of RARg to reverse RA resistance in NT2/D1-R1 cells (Moasser et al., 1995; Spinella et al., 1998) .
In summary, the findings presented suggest that a previously undercharacterized region of p53, the p53-NRD, may be responsible for the repression of basal p53 activity in the human EC cell line NT2/D1. We propose that while p53-NRD-mediated activity may be prominent in EC, it may also be important in other tumor types that possess wild-type p53, and may serve as a novel therapeutic target for such tumors. In germ cell tumors, as well as malignancies such as neuroblastomas, wild-type p53 is often found at high levels (Lutzker and Levine, 1996; Curtin et al., 2001) . It is possible that the p53-NRD may play a role in repression of basal p53 activity in germ cell, as well as non-germ cell tumor types. Insights into the mechanisms involved in p53-NRD-mediated repression may increase our understanding regarding the curability of germ cell tumors, and may impact on approaches to treat those tumors that harbor wild-type p53.
Materials and methods
Cell culture and drug treatment NT2/D1, NT2/D1-R1, Chinese hamster ovary (CHO), COS-1 cells, and the human breast cancer cell line MCF-7 were cultured in high glucose DME (Gibco BRL) with 10% fetal bovine serum supplemented with penicillin, streptomycin, and glutamine under humidified 5% CO 2 . Human bronchial epithelial cells (BEAS-2B) were cultured in serum-free LHC-9 medium (Biofluids) using established techniques (Langenfeld et al., 1997) . The RA induction protocols were as follows. On day À1, 1 Â 10 5 or 4 Â 10 5 cells were seeded into six-well plates or 10 cm dishes, respectively. On day 0, the medium was replaced with medium containing 10 mM RA or dimethyl sulfoxide (DMSO, 1 : 1000 dilution). TSA stock was 1 mg/ml in ethanol, and stored at À801C.
Western analysis
Exponentially growing cells were lysed in a modified RIPA buffer and analysed by SDS-PAGE, as described (Spinella et al., 1999) . Protein concentrations were determined using the Bradford technique. Gal4-DBD monoclonal antibody was purchased from Clontech and used at a concentration of 1 mg/ ml. Monoclonal p53 antibody (DO-1) was purchased from Santa Cruz Biotechnology, and used at a concentration of 2 mg/ml. Nuclear and cytosolic fractions from NT2/D1 and NT2/D1-R1 cells were isolated using the NE-PER nuclear extraction kit (Pierce). Protein concentrations were determined via the Detergent-Competent (D/C) method (Biorad). For detection of wild-type p53, equal amounts of nuclear or cytosolic lysate fractions from approximately 5 Â 10 6 NT2/D1 or NT2/D1-R1 cells were analysed by Western analysis using DO-1 antibody. For detection of gal4-DBD fusion proteins, 3 Â 10 5 NT2/D1 cells were transfected with 1 mg expression plasmid and harvested 24 h later as described above. Equal amounts of protein were analysed by Western analysis using gal4-DBD antibody conjugated to horseradish peroxidase RK5C1 (Santa Cruz).
Expression and reporter constructs
The human gal4-p53 expression and gal4-Luc reporter plasmids were kindly provided by Dr Tucker Collins (Harvard Medical School, MA, USA). The gal4-p53 plasmid encodes a fusion protein of the DNA-binding domain from the yeast protein Gal4, fused to the N-terminus of human p53 (Wadgaonkar and Collins, 1999) . The gal4-p53D117-274 expression plasmid, in which the central portion of p53 (amino acids 117-274) is deleted, was constructed by generating two p53 PCR fragments using gal4-p53 as a template. To facilitate in-frame ligation, a HindIII site was engineered at the junction of the two fragments. This introduced two non-native amino acids at the deleted junction. Other p53 truncation expression plasmids were constructed by a similar strategy.
The gal4-VPAD-NRD expression plasmid was created by fusion of a fragment of the VP16 activation domain generated using gal4-VP16 (Clontech) as a template, with a fragment encoding the residues 90-116 of p53, generated using gal4-p53 as a template. To facilitate in-frame ligation, a PstI site was engineered at the junction of the two fragments. This introduced two non-native amino acids at the junction (gal4-VP16AD-Leu-Gln-p53-NRD). gal4-VPAD-MYC was constructed in a similar manner, using an myc-his fragment cloned from pcDNA3.1myc-his B (Clontech).
A series of mutations were introduced into gal4-VPAD-NRD by PCR-based mutagenesis using the gal4-VPAD-NRD expression plasmid as a template. Briefly, primers were designed to introduce alanine substitutions at specific sites within the p53-NRD fragment of the construct. Using these primers, the mutated p53-NRD fragments were amplified through PCR. A restriction endonuclease digestion was then performed on gal4-VPAD-NRD to remove the wild-type p53-NRD fragment. Ligations were performed to introduce the mutated p53-NRD fragments into the expression plasmid, thereby replacing the wild-type p53-NRD fragment with the mutated p53-NRD fragment. The sequence of the amino-acid substitutions generated by PCR are depicted in the inset of Figure 5a . All constructs were confirmed by direct DNA sequencing.
Transient transfection reporter assays
Transfection of expression plasmids and reporter constructs was performed via calcium phosphate percipitation, as previously described (Curtin et al., 2001) . The ability of NT2/D1 and NT2/D1-R1 cells to activate gal4-p53 and gal4-p53 truncations was assessed upon cotransfection with a gal4-Luc reporter. A total of 0.75 mg reporter and 0.5 mg expression plasmid was used for each transfection experiment. CMV-bgal (0.5 mg) was included to normalize for transfection efficiency. For all reporter experiments, appropriate insertless expression vectors were used, as needed to equalize total DNA levels. Plates transfected with a given plasmid combination received a portion of the same calcium phosphate precipitate. Cells were exposed to DNA precipitates for 14-16 h, then washed and cultured with or without RA or TSA for an additional 24-48 h. Luciferase activity was measured and normalized to b-galactosidase activity, as previously reported (Curtin et al., 2001) . Unless otherwise specified, data points represent the average of triplicate transfections with similar results obtained in at least three independent experiments. Some transfections were performed using the Polyfect reagent (Qiagen), as per the manufacturer's protocol.
